EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) Just Acquired 30% of Psilocybin Player Pharmadelic Labs Corp. and May Be One of the Most Promising Companies to Watch Right Now in the Massive Shroom Boom!


Sponsored Content By: EGF Theramed Health Corp.
12:11 5/11/2020


The "Shroom Boom" Offers New and Exciting Possibilities for Medicine...

Magic Mushrooms Could Be the Big Answer to Treating Depression, PTSD, Addiction, Anxiety and Even Alzheimer's Disease!

The attitude towards drug reform has seen a seismic shift in acceptance on both sides of the political spectrum in recent years.

We have seen the legal cannabis boom take off and now 2/3rds of Americans are advocating for legal marijuana usage. Cannabis has generated considerable headlines these last few years and over 30 states now legalize the plant medicinally and 11 legalize it recreationally.

Who would have thought a decade ago that there would be multi-national publicly traded marijuana companies that are worth tens of billions of dollars today??

Legal cannabis was one of the most important investment trends of the last ten years but now the investment trend in psychadelic medicine is beginning to garner tremendous attention!

Psychadelic medicine could be this decade's most buzzed about topic!

The conversation around the psilocybin compound is getting louder and louder...

Changes to global attitudes in the last decade has seen legalization, followed by huge market growth, of medicines employing previously prohibited substances - cannabis being the leading example.

Leading scientists, academic institutions and government administrations are turning their attention to the benefits of psilocybin as a potential treatment for the global problems of mental health and end of life care!

More and more studies are examining the properties of this molecule, and the enormous effects that it can have on the huge global problem of treating mental health.

There is a small-cap company currently flying under the radar that is aiming to achieve the ability to produce this molecule quickly, economically, and cleanly to feed the growing demand for it.

EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) now owns 30% of Pharmadelic Labs and could be ready for a massive breakout as psilocybin continues to gain widespread acceptance!

30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs is not working to create drugs that require FDA approval and could take tens of years for approval. They instead are working to patent and create intellectual property that can mass produce pharmaceutical high-grade psilocybin for big pharma in a number of days versus weeks in an unsafe greenhouse environment.

The potential value of this IP could unlock huge profits and save years of scientific research for the many big pharma companies that will soon seek to enter the Psychedelic space and want to mass produce Psilocybin for use in their future drugs and therapeutics.

Pharmadelic Labs could hold the key to this success!

Very few companies will get an FDA drug approved, maybe a handful at best, hundreds of them will attempt to do so as the race has ultimately begun for Psychedelic billions as the sector opens up, but everyone will need an edge over their competition.

This edge is not in the drug itself or the molecule, or the compound, but may be in the process and the way the compound is mass produced in a lab environment.

This is where 30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs comes into the equation and may offer the key to success and the solution that hundreds of pharma companies need to gain that edge over their competition.

Any Big Pharma company that acquires or licenses Pharmadelic Labs IP would have something equivalent to a magical oven that every chef dreams about having in his restaurant to gain that little extra edge over the competition!

Greetings All,

Psilocybin is a psychoactive substance found in around 200 species of mushroom.

Much of the science remains surrounding the molecule remains unexplored, but it has been theorized that psilocybin works with the body's serotonin system to heighten emotional responses, which helps to actively confront mental health issues such as depression.

Did you know psilocybin was designated Schedule I in the 1970 Criminal Substances Act, making it a drug with "no currently accepted medical use and a high potential for abuse".

However, this was largely a politically motivated decision made to oppose 1960s counterculture!

Research with psychedelics was first started in the 1950s and ‘60s but abruptly ended in the early 1970s in response to unfavorable media coverage.

Magic mushrooms in fact are the safest “recreational” drug to take and those who take them are the most sensible and well prepared, according to the 2017 Global Drug Survey. Out of almost 10,000 people who took them, only 0.2% needed emergency medical treatment.

Ongoing clinical trials are discovering the uses of psilocybin in the treatment of addiction and other mental health problems.

A 60 Minutes documentary broadcast in October of 2019 has explored current efforts to treat harmful mental health issues and is worth watching.

Johns Hopkins University is the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.

Its publication on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide!

The University began clinical trials on the potential positive effects of the drug when it comes to aiding treatment-averse depression, addiction, and anxiety.

The results were so promising that the institution published an article arguing that psilocybin should be considered a Schedule 5 drug!

At the Center for Psychedelic and Consciousness Research, researchers will now focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health.

Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use in people with major depression.

Not long ago, residents of Denver, Colorado voted to decriminalize the drug, and Oakland, California’s city council unanimously concluded that consuming numerous psychedelic plants, mushrooms included, should not be considered criminal.

This year Santa Cruz become the latest city to decriminalize "magic mushrooms" and other natural psychedelics, including ayahuasca and peyote.

The movement to decriminalize the drug has since picked up steam across the U.S. and Chicago and other cities may be next!

Investors may soon be tripping for an opportunity to explore the Mushroom Rush and 30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs could become one of the biggest winners in the arena!

https://pharmadeliclabs.com/

Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds - primarily psilocybin, the psychoactive component of magic mushrooms.

The company has begun to research psilocybin and psychedelics extraction and processing for its Las Vegas extraction lab. R&D will continue in labs in British Columbia and Alberta in Canada where psychedelic research is legal.

"We are very excited to enter the Psilocybin space as we feel it is very complimentary to the CBD space as both carry unique and undeniable health benefits,” stated CEO David Bentil.

George Anstey, Chief Executive Officer of Pharmadelic Labs stated, "We are excited that EGF Theramed Health recognizes the huge potential of the psilocybin market in treating mental health. We look forward to collaborating on innovative processes using synthetic DNA taken from mushrooms to produce a final product that will be made quicker, cheaper, and of a higher and more consistent quality than growing the product under traditional production methods."

EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) through its 30% owned Pharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways for creating compounds.

This has great potential for application in the pharmaceuticals industry!

Pharmadelic Labs’s patent portfolio will develop as follows:

  • File for provisional patent applications
  • Continue to update patents as technology develops
  • Strengthen existing patents with further applications around biosynthesis pathways as results are known

THE OPTIMAL PROCESS

Pharmadelic Labs biosynthesis process is clean and economical, and much quicker than cultivating mushrooms by themselves – approximately 3 days rather than up to 10 weeks!

It also ensures consistent levels of psilocybin and is safe due to yeast’s status as Generally Recognized as Safe (GRAS).

The company will also be providing an effective alternative to chemical synthesis. Chemical synthesis of psilocybin costs upwards of $7,000 per gram, which is far more expensive than the company's methods.

Here is how the biosynthesis of psilocybin works:

Step 1
Order synthetic DNA from hallucinogenic mushrooms

Step 2
Install DNA into genome of industrial brewing yeast

Step 3
Cultivate yeast on a large scale

Step 4
Extract psilocybin

Step 5
Create pharmaceutical product

THE MARKET - MENTAL HEALTH

Mental health is increasingly recognized as one of the biggest medical issues in the world. This costs countries both directly, through medication and hospitalization, and indirectly, through productivity losses.

  • According to the Centers for Disease Control, suicide was the 10th leading cause of death in the US in 2017.
  • Healthypeople.gov has found that in any given year, over 18% of US adults suffer from mental illness.
  • Forbes has reported that mental illness costs the U.S. economy nearly $200 billion a year.
  • According to Brands Essence Research, the global antidepressant drugs market was estimated to be over $13.5 billion in 2018 and is predicted to rise to nearly $16 billion by 2025.

Positive Headlines on Psychedelics are Piling Up!

A single dose of the psychedelic ingredient in "magic mushrooms" may bring long-lasting relief to cancer patients who suffer anxiety and depression, a new, small study suggests. (SOURCE)

Doctors Are Turning to Psychedelics to Treat Depression and Addiction (SOURCE)

A Radical Approach to Beating Addiction (SOURCE)

Doctors Are Giving Alzheimer's Patients LSD (SOURCE)

Researchers from the University of South Florida discover that psilocybin can also bind itself to receptors that stimulate healing. (SOURCE)

Meet the Pharmadelic Labs Team

George Anstey -- CEO

For the past decade, George’s entrepreneurial mind has been focused on the booming cannabis industry: contracting with commercial license holders like Broken Coast Cannabis, a medical cannabis company bought by Aphria for $230 million CAD in 2018. George now consults on compliance matters for early-stage cannabis companies, helping those organizations to navigate the license application requirements set by Health Canada. This experience in guiding new industries will be invaluable in promoting psilocybin.

George is from Victoria BC, on the West Coast of Canada and was educated at the University of Victoria’s School of Business. Outside of work, George can be found hiking, fishing and mushroom- hunting in the coastal rainforests of the Pacific Northwest.

Brent Staples -- CSO

Brent has been heavily involved in metabolic engineering of industrial brewing yeasts for the development of novel fermented products. In addition to this, he focuses on the analysis of metabolites corresponding to genomic changes. He is now working on engineering synthetic metabolic pathways for the biosynthesis high-value molecules in microorganisms to meet the growing demand for cleaner, renewable chemistries. It is Brent’s enviable knowledge in this area that has allowed Pharmadelic Labs to develop its innovative method of biosynthesising psilocybin.

Brent is from Victoria, Canada, where he studied biochemistry at the University of Victoria, with a focus on synthetic biology and medicinal chemistry.

J.H. Lipton -- CFO

J.H. Lipton is an expert in his field, having practiced corporate tax and securities law for over three decades. As senior counsel and he also holds further business and professional qualifications in the form of an MBA and CFA. He provides the company with a broad diversified knowledge of financial and legal management that will benefit the company across many areas.

Previously, Lipton has held posts as a investment banker and senior executive across a wide and diversified group of companies and industries. With extensive experience in capital markets and technology he lends managerial capacity and credibility to Pharmadelic Labs’ corporate endeavors. Leaning on several decades of legal and corporate experience he will act as Chief Financial Officer and as General Counsel.

THE BOTTOM LINE

The burgeoning psychedelics sector is gaining global media attention and there has been a meteoric rise of psychedelic stocks.

The reform movement for psilocybin is gaining momentum in North America and is showing many of the same hall marks as the cannabis industry did in its earliest days.

Another company in the arena that has been creating some major buzz is Toronto traded MindMed, who had Shark Tank investor Kevin O’Leary as part of its investment round.

Something is going on if one of TV’s long standing “shark” investors are interested in the psychedelic boom!

To reiterate, 30% owned Pharmadelic Labs is not working to create drugs that require FDA approval and could take tens of years for approval. They are working to patent and create intellectual property that can mass produce pharmaceutical high-grade psilocybin for big pharma in a number of days compared to weeks in an unsafe greenhouse environment!

The potential value of this IP could unlock huge profits and save years of scientific research for the many big pharma companies that will soon seek to enter the Psychedelic space and want to mass produce Psilocybin for use in their future drugs and therapeutics.

30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs may offer the key to success and the solution that hundreds of pharma companies need to gain that edge over their competition!

The Shroom Boom is a very exciting situation unfolding and is capturing the attention of cannabis investors and those who may have missed out on that Green Rush.

There are only a handful of publicly traded companies in this space and demand for investments in this new and emerging arena could be concentrated in just a few stocks.

With psilocybin being studied to treat a multitude of health issues, the pharmaceutical industry will be reliant on products containing the compound.

GW Pharmaceuticals became well known for its popular cannabidiol (CBD)-based drug, Epidiolex. It is the first FDA approved medication made from cannabis and has produced millions upon millions in revenue for the company.

The potential for shrooms in big pharma is astonishing!

The fact that 30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs only has a little over 8 million shares outstanding could send this stock soaring as traders learn more about it!

30% EGF Theramed Health Corp.(CSE: TMED | OTCQB: EVAHF) owned Pharmadelic Labs could be the next hot Biotech stock to explode as the company capitalizes on the rapidly growing Psilocybin movement!

Sources:
https://pharmadeliclabs.com/about
https://news.gallup.com/poll/267698/ support-legal-marijuana-steady-past-year.aspx
https://www.theguardian.com/lifeandstyle/2017/may/29/ safe-magic-mushrooms-psilocybin-drug-depression- illegal
https://www.playboy.com/read/the-future-of-magic-mushrooms
https://hopkinspsychedelic.org/
https://www.usnews.com/news/health-news/articles/ 2020-01-28/psychedelic-drug-eases-cancer-patients-distress- long-term
https://www.mensjournal.com/health-fitness/ why-doctors-are-turning-to-psychedelics-to-treat-depression- addiction/?fbclid=IwAR3koUkNxs3hLsEhLgy65ebp- gyRkgeF1zQnYHWmKxzwvs7Q4nN7pTcO3_4
https://www.psychologytoday.com/us/articles/ 201705/radical-new-approach-beating-addiction
https://futurism.com/neoscope/doctors-giving-alzheimers-patients-lsd
https://link.springer.com/article/10.1007/s00221-013-3579-0
https://observer.com/2019/12/microdosing-ibogaine- psychedelic-drugs-shark-tank-kevin-oleary-mindmed/




Disclaimer: Pursuant to an agreement between EGF Theramed Health Corp. and DearWallstreet.com, we were hired to publicly disseminate information about (( EVAHF )) including on the Website and other media including Facebook and Twitter. We were paid up to $100,000 in cash from Electrik Dojo. We own zero shares of (( EVAHF )) which we purchased in the open market. We may buy or sell additional shares of (( EVAHF )) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.